Serotonergic status in patients with hereditary vascular retinopathy syndrome

C W J M Storimans, D Fekkes, A van Dalen, E D Bleeker-Wagemakers, J A Oosterhuis

Abstract

Aim/background—In a new autosomal dominant syndrome (which the authors called hereditary vascular retinopathy (HVR)) cerebral ischaemia, Raynaud’s phenomenon, and migraine are the most striking features. As serotonin (5-HT) is known to play a role in vasoconstrictive processes, Raynaud’s phenomenon, and migraine they wondered whether the serotonergic status in patients with HVR is different. Therefore, it was decided to investigate some serotonergic variables in these patients.

Methods—The study was conducted in 12 patients with HVR, 10 relatives, and 19 healthy controls. The levels of intraplatelet and plasma 5-HT were measured, as well as the plasma levels of its precursor amino acid tryptophan and the ratio of tryptophan to the large neutral amino acids, which compete with the transport of tryptophan through the blood-brain barrier.

Results—In both the patients with HVR and in nine relatives the concentrations of 5-HT in plasma and platelets were significantly lower than in controls. The plasma levels of tryptophan and the tryptophan ratio were also found to be lower in the patient group compared with the control group, but not in the relatives.

Conclusion—The observed alterations in 5-HT and its precursor tryptophan strongly suggest the existence of a malfunctioning of the serotonergic system in the HVR syndrome.

Medical Centre
Molendael, Soest
C W J M Storimans

Section
Pathophysiology of
Behaviour, Erasmus
University, Rotterdam
D Fekkes
A van Dalen

The Netherlands
Ophthalmic Research
Institute, Amsterdam
E D Bleeker-Wagemakers

Ophthalmological
Department, Leiden
University
J A Oosterhuis

Correspondence to:
D Fekkes, Section of
Pathophysiology of
Behaviour, Erasmus
University, Rotterdam,
PO Box 1700, 3000 DR
Rotterdam, Netherlands.

Accepted for publication
22 January 1998

Hereditary vascular retinopathy (HVR) is characterised by retinal microangiopathy, cotton wool patches (oedema, swelling, and degeneration of the nerve fibres), retinal haemorrhages, areas of capillary non-perfusion, and in more advanced stages occlusion of large retinal vessels causing large avascular areas which may induce a neovascular response (Fig 1).1 The retinopathy becomes symptomatic around the age of 40 years, giving a gradual decrease of visual acuity, transient visual disturbances, and visual field defects. At the age of 60 years, most patients experience severe visual impairment even up to blindness.

We examined a large pedigree spanning three generations showing an autosomal dominant pattern of inheritance.2 Apart from the retinopathy, a high prevalence of Raynaud’s phenomenon and migraine was found in this family. Moreover, mental symptoms such as loss of memory and aggressive behaviour were mentioned in some members of this family. Five out of seven HVR patients who were examined neurologically also showed cerebral vascular involvement.3 Since it is known that serotonin (5-HT) plays some role in vasospasm,4 Raynaud’s phenomenon,5 migraine,6 and aggression7 we decided to determine some serotonergic variables in these patients.

5-HT is mainly synthesised in enterochromaffin cells of the gut. After release in the blood, 5-HT is taken up by the platelets or inactivated by the liver and the lungs. Consequently, the concentrations of 5-HT in plasma are rather low.10 It is assumed that 5-HT in plasma represents a distinct pool with a rapid turnover, different from 5-HT in platelets which represents a reserve pool with a slow turnover.11 Biondi et al1 reported that migraine patients have chronically low systemic 5-HT. Between attacks, plasma levels of 5-HT were about 60% lower compared with healthy control subjects, while platelet 5-HT levels were normal. Besides, no changes were demonstrated for 5-HT precursor plasma levels.

Because of the above mentioned frequent occurrence of Raynaud’s phenomenon and migraine in HVR, we wondered what the serotonergic status in these patients would be. For this reason, we determined the concentrations of 5-HT in blood platelets and plasma, the plasma concentration of its precursor, the amino acid tryptophan, and the ratio of tryptophan to the other large neutral amino acids. The latter compete with tryptophan for the transport carrier at the blood-brain barrier. This tryptophan ratio is a measure of the amount of 5-HT synthesised in the brain,13 which may correlate with the incidence of aggression.

Subjects and methods

We studied 12 patients suffering from HVR (seven females, five males, aged 47 (SD 12) years), 10 relatives (five females, five males, aged 36 (8) years), and 19 controls (nine females, 10 males, aged 36 (6) years), healthy individuals from among the hospital staff. The criteria for diagnosis of HVR were the presence of funduscopic and/or angiographic abnormalities—that is, microangiopathy, cotton wool patches (oedema, swelling, and
of the same material. The mobile phase consisted of 75 mM sodium acetate, 0.27 mM disodium EDTA, 2.13 mM heptane sulphonate acid, and 20% methanol, pH 4.15. The flow rate was set at 0.4 ml/min and the column temperature was 40°C. The detection system consisted of a Model 5100A Coulochrom detector equipped with a 5021 conditioning cell and a 5011 high sensitivity cell (ESA, Bedford, MA, USA). The potentials for the conditioning cell and detectors 1 and 2 were −0.06, +0.03 and +0.48 V, respectively (gain 10 × 100). The detector was linked to a HP 3396A integrator (Hewlett Packard) and quantification was done by measuring peak heights. The recovery of 5-HT added to the plasma samples was 90–98%.

Tryptophan was determined by HPLC after deproteinizing the plasma with 3% (w/v) trichloroacetic acid in the presence of methyl tryptophan as internal standard. Samples of 30 µl were injected onto a 125 × 4 mm Lichrospher 100 RP-18 5 µm column (Merck, Darmstadt, Germany), which was protected by a 4 × 4 mm guard column of the same material. The mobile phase was composed of 10 mM KH2PO4 pH 3.6, which contained 10% methanol and was delivered at a flow rate of 0.8 ml/min at 30°C. Detection was accomplished at 278 nm (10 nm bandwidth) using a Hewlett Packard multiple wavelength detector (reference wavelength 450 nm, bandwidth 80 nm). Recoveries for added tryptophan were 94% (5%) (mean (SD), n=10).

Other amino acids were determined using an LKB 4400 amino acid analyser with fluorescence detection.13 The plasma tryptophan ratio was determined by dividing the plasma tryptophan concentration by the sum of the other large neutral amino acids—that is, valine, isoleucine, leucine, tyrosine, and phenylalanine. This ratio is a measure for the amount of tryptophan entering the brain, which is subsequently available for the synthesis of 5-HT.13

STATISTICAL ANALYSIS
All data are presented as mean (SD). Differences between the patient groups and the control group were assessed by one way analysis of variance (ANOVA). The Bonferroni multiple comparison test was selected as post-test to compare pairs of group means. The minimum level of significance was considered as p<0.05 (two tailed).

Results
All serotoninergic variables measured differed between the patient groups and the control group (ANOVA; p values ranged between <0.001 and 0.0138). The p values and F ratios for each variable are shown in Table 1. With the Bonferroni test for individual variables, it was found that the plasma 5-HT concentration in the 12 HVR patients (5.6 (1.4) nmol/l) was significantly lower than in the controls (9.8 (2.8) nmol/l, p <0.001; Table 1 and Fig 2). In the relatives, except for one, the plasma 5-HT level was also decreased (3.1 (1.1) nmol/l; p<0.001). The platelet 5-HT contents in HVR patients and relatives (2.2 (0.8) and 2.0 (0.9)
Table 1 Biochemical variables in hereditary vascular retinopathy (HVR) patients, relatives, and healthy controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>Controls (n=19)</th>
<th>HVR patients (n=12)</th>
<th>Relatives (n=9)</th>
<th>One way ANOVA p value</th>
<th>F value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma 5-HT (nmol/l)</td>
<td>9.8 (2.8)</td>
<td>5.6 (1.4)*</td>
<td>5.1 (1.1)*</td>
<td>&lt;0.0001</td>
<td>20.91</td>
</tr>
<tr>
<td>Platelet 5-HT (nmol/10^9 platelets)</td>
<td>3.2 (0.6)</td>
<td>2.2 (0.8)*</td>
<td>2.0 (0.9)*</td>
<td>0.0001</td>
<td>11.84</td>
</tr>
<tr>
<td>Plasma tryptophan (µmol/l)</td>
<td>51 (8)</td>
<td>42 (6)*</td>
<td>45 (6)</td>
<td>0.0024</td>
<td>7.11</td>
</tr>
<tr>
<td>Tryptophan ratio</td>
<td>8.7 (0.9)</td>
<td>7.7 (1.1)*</td>
<td>7.8 (1.0)</td>
<td>0.0138</td>
<td>4.82</td>
</tr>
</tbody>
</table>

Data are presented as mean (SD).

*Significantly different from control group (p<0.001); †Significantly different from control group (p<0.01); ‡Significantly different from control group (p<0.05; Bonferroni test).

As mentioned, one relative showed a deviating plasma 5-HT level (30.5 nmol/l). This woman also differed from the other relatives in plasma tryptophan level (57 µmol/l). One year later another blood sample was taken and the plasma was reanalysed. The concentration of 5-HT was even higher in this sample than the year before. Therefore, her biochemical variables were not taken into account in the analyses.

Discussion

Serotonin is known to be involved in the pathogenesis of Raynaud’s phenomenon and migraine, and it also plays a role in vasoconstriction.

In the HVR syndrome occlusion occurs in the retinal and possibly the cerebral vessels. Moreover, 80% of the patients with the retinopathy suffer from Raynaud’s phenomenon and 60% suffer from migraine. In the family studied, plasma 5-HT, platelet 5-HT content, and plasma tryptophan levels are decreased; not only did the HVR patients show these abnormalities but also the relatives studied. The low plasma levels of 5-HT in the study group are probably not due to the occurrence of migraine, because the subjects without migraine had the same plasma 5-HT concentrations as those with migraine. Since six of the eight relatives with these abnormalities suffered from migraine or Raynaud’s phenomenon (one subject even suffered from both conditions), it is possible that these people—being also younger than the HVR patients—are still at risk of developing the retinopathy in future, indicating that these decreased biochemical variables are trait markers.

Several mechanisms may account for these abnormal values: (1) malabsorption of tryptophan in the intestinal mucosa, (2) increased conversion of tryptophan into the coenzyme nicotinamide, acetyl CoA, and acetocetyl CoA (the kynurenin pathway), (3) increased utilisation of 5-HT and consequently of tryptophan, and (4) increased excretion of tryptophan. There were no indications of low intestinal tryptophan intake in these patients. Moreover, it has been suggested that food intake does not affect plasma and whole blood 5-HT. The exact mechanism for the observed differences cannot yet be determined.

In conclusion, we found a derangement in the serotoninergic system of patients suffering from HVR and in their relatives. Whether...
5-HT is pathophysiologically or aetiologically involved in vascular retinopathy or the abnormal 5-HT status in this syndrome is an epiphenomenon requires further investigation.

7 Humphrey PPA. 5-Hydroxytryptamine and the pathophysiology of migraine. *J Neurol* 1991;238:S38–44.